Pancreatic Cancer Diagnostics Market: By Type Of Test (Blood Tests, Biopsy, Biological Markers), By Type Of Cancer (Adenocarcinoma, Squamous carcinoma, Adenosquamous carcinoma), By End User (Hospitals, Oncology Institutes, Diagnostic Centres), and Geography.  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Pancreatic Cancer Diagnostics Market size was valued at USD 3,562.51 million in 2022 and is poised to grow at a CAGR of 8.9% from 2023-2029. Pancreatic cancer will begin in tissues of pancreas. Pancreas secretes enzymes which helps in the digestion and manage blood sugar levels. pancreatic cancer diagnostics market rapidly spreads to the nearby organs. Often it can be diagnosed at early stages in people with pancreatic cyst or family history of pancreatic cancer. Most common sign of pancreatic cancer is diabetes which occurs along with loss of weight, pain in the upper abdomen and that spreads to the back. This development can be attributed to patients' desire for comprehensive therapy and the availability of enhanced instruments and knowledge. Due to an increase in the consumption of alcohol and cigarettes, as well as changes in lifestyle, the market for pancreatic cancer diagnostics is growing. Furthermore, widespread use of high-cost medications such as Abraxane injection and Gemzar to treat pancreatic cancer boosts the market. Technologies for timely diagnosis of pancreatic cancer are yet to develop at a full stretch which may results in early diagnosis of advanced stage of pancreatic cancer and can provide rightful treatment. Moreover, major players are getting collaborated with government and other social responsible agencies to improve the patient accessibility and affordability towards the treatments and diagnosis. For example, Illumina, Inc. has launched a venture called GRAIL along with Billgates and Jeff Bezos as investors with $100 Mn to focus on the blood based cancer screening for early and timely diagnosis of the common tumours through simple laboratory tests.

Global Pancreatic Cancer Diagnostics Market Summary

Study Period

2023-29

Base Year

2022

CAGR

8.9%

Largest Market

North America

Fastest Growing Market

North America
Pancreatic Cancer Diagnostics Market Dynamics

Increasing prevalence of pancreatic cancer is expected to accelerate the growth of pancreatic cancer diagnostics market. According World Cancer Research Fund International, pancreatic cancer is the 12th most common cancer, and it has estimated that about 3, 38,000 cases were diagnosed with pancreatic cancer in 2012. Moreover, Growing awareness and concern about the disease, increase in healthcare expenditure, technological advancements and innovation of new products, large number of unmet needs related to disease are the few factors which are expected to fuel the growth of pancreatic cancer diagnostics market. However, limited options for treatment, inaccurate and inadequate results of the diagnosis, high cost associated with the tests are major restraints of pancreatic cancer diagnostics market.

Key Features of the Reports

  • The pancreatic cancer diagnostics market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Pancreatic Cancer Diagnostics Market Segmentation

By Type Of Test
  • Blood Tests
  • Biopsy
  • Biological Markers
By Type Of Cancer
  • Adenocarcinoma
  • Squamous carcinoma
  • Adenosquamous carcinoma
By End User
  • Hospitals
  • Oncology Institutes
  • Diagnostic Centres

Frequently Asked Questions

The pancreatic cancer diagnostics market size was valued at USD 3,562.51 million in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

Ambry Genetics (U.S) Abbott Laboratories, Inc.(U.S) AstraZeneca plc (U.K) Eli Lilly and Company(U.S.) BioMeriux SA (France) Illumina, Inc.(U.S) Genoptix, Inc. (U.S.)

1. Executive Summary
2. Global Pancreatic Cancer Diagnostics Market Introduction 
2.1.Global Pancreatic Cancer Diagnostics Market  - Taxonomy
2.2.Global Pancreatic Cancer Diagnostics Market  - Definitions
2.2.1.Type of Test
2.2.2.Type of Cancer
2.2.3.End User
2.2.4.Region
3. Global Pancreatic Cancer Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Pancreatic Cancer Diagnostics Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Pancreatic Cancer Diagnostics Market  By Type of Test, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Blood Tests
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Biopsy
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Biological Markers
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Pancreatic Cancer Diagnostics Market  By Type of Cancer, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Adenocarcinoma
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Squamous carcinoma
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Adenosquamous carcinoma
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Pancreatic Cancer Diagnostics Market  By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Oncology Institutes
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Diagnostic Centres
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Pancreatic Cancer Diagnostics Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Pancreatic Cancer Diagnostics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Type of Test Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Blood Tests
9.1.2.Biopsy
9.1.3.Biological Markers
9.2.  Type of Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Adenocarcinoma
9.2.2.Squamous carcinoma
9.2.3.Adenosquamous carcinoma
9.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals
9.3.2.Oncology Institutes
9.3.3.Diagnostic Centres
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Pancreatic Cancer Diagnostics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Type of Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Blood Tests
10.1.2.Biopsy
10.1.3.Biological Markers
10.2.  Type of Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Adenocarcinoma
10.2.2.Squamous carcinoma
10.2.3.Adenosquamous carcinoma
10.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Oncology Institutes
10.3.3.Diagnostic Centres
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11. Asia Pacific (APAC) Pancreatic Cancer Diagnostics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Type of Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Blood Tests
11.1.2.Biopsy
11.1.3.Biological Markers
11.2.  Type of Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Adenocarcinoma
11.2.2.Squamous carcinoma
11.2.3.Adenosquamous carcinoma
11.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Oncology Institutes
11.3.3.Diagnostic Centres
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Pancreatic Cancer Diagnostics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Type of Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Blood Tests
12.1.2.Biopsy
12.1.3.Biological Markers
12.2.  Type of Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Adenocarcinoma
12.2.2.Squamous carcinoma
12.2.3.Adenosquamous carcinoma
12.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Oncology Institutes
12.3.3.Diagnostic Centres
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Pancreatic Cancer Diagnostics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Type of Test Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Blood Tests
13.1.2.Biopsy
13.1.3.Biological Markers
13.2.  Type of Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Adenocarcinoma
13.2.2.Squamous carcinoma
13.2.3.Adenosquamous carcinoma
13.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Oncology Institutes
13.3.3.Diagnostic Centres
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Ambry Genetics (U.S)
14.2.2.Abbott Laboratories, Inc.(U.S)
14.2.3.AstraZeneca plc (U.K)
14.2.4.Eli Lilly and Company(U.S.)
14.2.5.BioMeriux SA (France)
14.2.6.Illumina, Inc.(U.S)
14.2.7.Genoptix, Inc. (U.S.)
14.2.8.F. Hoffmann-La Roche Ltd. (Switzerland)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Ambry Genetics (U.S)
  • Abbott Laboratories, Inc.(U.S)
  • AstraZeneca plc (U.K)
  • Eli Lilly and Company(U.S.)
  • BioMeriux SA (France)
  • Illumina, Inc.(U.S)
  • Genoptix, Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (U.S.)
  • GlaxoSmithKline plc (UK)
  • Amgen, Inc.(U.S)
  • Celgene corporation (U.S)
  • Novartis AG (Switzerland)